Ascendis Pharma AS
Ownership
Ownership Structure
Who owns Ascendis Pharma AS (ASND)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 99.8% of the shares are freely tradable; institutional investors hold 103.9%.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 0.34 | 225,155 | +68.9 | 06/30/2026 |
| Neuberger Berman Group LLC | 0.22 | 142,705 | +0.0 | 06/30/2026 |
| ODDO BHF Asset Management SAS | 0.20 | 128,657 | +0.0 | 06/30/2026 |
| Quadrature Capital Limited | 0.06 | 40,845 | +0.0 | 06/30/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Janus Henderson Hrzn Biotec E2 USD | 0.35 | 228,416 | +0.0 | 03/31/2026 |
| Spyglass US Growth F USD Inc | 0.11 | 69,317 | -0.9 | 03/31/2026 |
| Invesco NASDAQ Next Gen 100 ETF | 0.05 | 29,931 | +0.5 | 04/20/2026 |
| Russell Inv Tax-Managed US Mid&Sm Cap S | 0.02 | 15,611 | +0.0 | 09/30/2026 |
| First Trust Long/Short Equity ETF | 0.02 | 15,461 | +0.0 | 04/20/2026 |
| Rhenman Healthcare Equity L/S RC2 SEK | 0.02 | 15,000 | +0.0 | 01/31/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider holdings
| Person | Role | Shares | Value | As of | Type |
|---|---|---|---|---|---|
| Holtug Lars | Director | 4,000 | 1,101,600 $ | Sep 2, 2026 | direct |
| Bienaime Jean Jacques | Director | 2,900 | 798,660 $ | Aug 14, 2026 | direct |
Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.
Insiders
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 8, 2026 | Bodenhoff Mads | SVP & PAO | Sell | 3,000 | 270.19 | 810,570 |
| Sep 8, 2026 | Bodenhoff Mads | SVP & PAO | Other | 3,000 | 110.00 | 330,000 |
| Sep 2, 2026 | Holtug Lars | Director | Sell | 236 | 264.13 | 62,335 |
| Aug 14, 2026 | Bienaime Jean Jacques | Director | Buy | 900 | 246.91 | 222,219 |
| Aug 14, 2026 | Bienaime Jean Jacques | Director | Buy | 1,100 | 245.85 | 270,435 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →
Data as of: November 13, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.